Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismTumor-associated glycoprotein 72 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.
0 Patents (Medical) associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.
100 Deals associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.
100 Translational Medicine associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.